JPH08103457A - Intraocular lens - Google Patents

Intraocular lens

Info

Publication number
JPH08103457A
JPH08103457A JP26468694A JP26468694A JPH08103457A JP H08103457 A JPH08103457 A JP H08103457A JP 26468694 A JP26468694 A JP 26468694A JP 26468694 A JP26468694 A JP 26468694A JP H08103457 A JPH08103457 A JP H08103457A
Authority
JP
Japan
Prior art keywords
drug
eye
intraocular lens
medicine
characterized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP26468694A
Other languages
Japanese (ja)
Other versions
JP3640690B2 (en
Inventor
Tsutomu Sunada
力 砂田
Original Assignee
Nidek Co Ltd
株式会社ニデック
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nidek Co Ltd, 株式会社ニデック filed Critical Nidek Co Ltd
Priority to JP26468694A priority Critical patent/JP3640690B2/en
Publication of JPH08103457A publication Critical patent/JPH08103457A/en
Application granted granted Critical
Publication of JP3640690B2 publication Critical patent/JP3640690B2/en
Anticipated expiration legal-status Critical
Application status is Expired - Fee Related legal-status Critical

Links

Abstract

PURPOSE: To effectively suppress a complication after surgery by predicting the generation after the surgery by providing a gradual medicine releasing means for absorbing or holding a medicine and for gradually releasing that medicine into an eye after the lens is inserted to the eye concerning the intraocular lens to be inserted to the eye after the crystalline lens is removed.
CONSTITUTION: The intraocular lens is provided with an optical part 1 equipped with refracting power and generally formed for a convex lens and supporting parts 2 for supporting and fixing this optical part 1 inside the eye. Two supporting parts 2 are provided and respectively extended while being circumferentially bend in counter to the diameter direction of the optical part 1 and with its elastic power, the optical part 1 is supported. In this case, medicine containing parts 3 for containing the medicine of medical treatment to suppress the complication after the surgery such as an inflammation or congenital cataract are fitted to the supporting parts 2 on the side of the optical part 1 so as not to disturb surgical manipulations. These medicine containing parts 3 are composed of the materials of water-contained or oil-contained polymers and provided with functions for gradually releasing the liquid-state medicine contained in these materials inside the eye.
COPYRIGHT: (C)1996,JPO

Description

【発明の詳細な説明】 DETAILED DESCRIPTION OF THE INVENTION

【0001】 [0001]

【産業上の利用分野】本発明は、水晶体を取り除いた後に眼内に挿入される眼内レンズに関する。 The present invention relates to relates to intraocular lenses to be inserted into the eye after removal of the crystalline lens.

【0002】 [0002]

【従来の技術】白内障の治療としては、水晶体を摘出した後に眼内レンズを挿入する眼内レンズ手術がある。 The treatment of the Prior Art Cataract, there is an intraocular lens surgery to insert an intraocular lens after removal of the crystalline lens. 眼内レンズ手術は近年急速に進歩し、その安全性が飛躍的に向上し、手術の中でも最も安全な手術の部類に挙げられるほどになったといわれている。 IOL surgery rapidly progress in recent years, its safety is said to dramatically improved, became more like the class of the safest surgical among surgery. 従来眼内レンズ手術では、薬剤としては手術に直接必要な麻酔、ヒアルロン酸ナトリウム、生理食塩水等を使用するにすぎなかった。 In the conventional intraocular lens surgery, directly required anesthesia surgery as a drug was only used sodium hyaluronate, physiological saline or the like.

【0003】このように安全な手術として確立された眼内レンズ手術においても、術後の炎症や後発白内障、といった水晶体を取り去ること自体に起因すると考えられる術後合併症がある。 [0003] In this way, secure established IOL surgery as surgery, there is a postoperative complication of attributed itself be removed postoperative inflammation and cataract, such a lens. これら合併症の問題に対し、生体内での適合性を向上させるべく眼内レンズの表面を処理するという試みがある。 For these complications problems, there is an attempt that treating the surface of intraocular lenses in order to improve the compatibility in vivo. また、合併症を抑制する薬剤も開発されており、眼内レンズの表面にこれら薬剤を塗布する試みもある。 Moreover, the drug has also been developed to suppress complications, some attempts to apply these agents to the surface of the intraocular lens.

【0004】 [0004]

【発明が解決しようとする課題】しかしながら、眼内レンズの表面処理による方法は、種々のものが提案されているが、有効性、安定性、コストの点で満足できる物はいまだ存在しない。 [SUMMARY OF THE INVENTION However, the method according to the surface treatment of the intraocular lens, although various types have been proposed, effectiveness, stability, no still present satisfactory in terms of cost. また、眼内レンズへの薬剤の塗布も予防や治療に要するほどの量を含むことはできない。 Moreover, it is not possible to include an amount enough even coating of the agent to the intraocular lens required for the prevention and treatment. しかも、比較的長い時間その効果を保持することはできない。 Moreover, it is impossible to hold a relatively long time its effect.

【0005】本発明は、上記のような事情に鑑み、眼内レンズ手術において発生の予想される術後合併症の抑制、さらには、術前からの内眼的疾患の治療のために薬剤を効率よく投与できる眼内レンズを提供することを技術課題とする。 [0005] The present invention has been made in view of the circumstances as described above, inhibition of the expected post-operative complications occurred in intraocular lens surgery, further, an agent for the treatment of intraocular disorders from preoperative and an object to provide an intraocular lens which can be administered efficiently.

【0006】 [0006]

【課題を解決するための手段】本発明は、上記課題を解決するために、次のような構成を持つことを特徴とする。 SUMMARY OF THE INVENTION The present invention, in order to solve the above problems, characterized by having the following configuration. (1) 水晶体を取り除いた後に眼内に挿入される眼内レンズにおいて、液体の薬剤または液体に溶解した薬剤を吸収もしくは保持するとともに、眼内に挿入後に吸収もしくは保持した薬剤を徐々に眼内に放出する薬剤徐放手段を設けたことを特徴とする。 (1) In the intraocular lens to be inserted into the eye after removal of the crystalline lens, while absorbing or retaining the agent dissolved in the drug or liquid fluid, slowly drug absorbed or retained after insertion into the eye an intraocular characterized in that a drug release means for releasing the.

【0007】(2) (1)の薬剤徐放手段の材質は含水性又は含油性の材質からなり、液体の薬剤または液体に溶解した薬剤を吸収含有することを特徴とする。 [0007] (2) Material of the drug release means (1) consists of water or oil retainability of material, characterized in that it contains absorbing agent dissolved in the drug or liquid fluid.

【0008】(3) (2)の眼内レンズは、屈折力を持つ光学部と、該光学部を眼内に支持固定するための支持部を有し、前記薬剤徐放手段は前記光学部または支持部に取り付けたことを特徴とする。 [0008] (3) The intraocular lens (2) has an optical portion having a refractive power, a support portion for supporting and fixing the optical faculties in the eye, the drug release means is the optical portion or characterized in that attached to the support portion.

【0009】(4) (2)の薬剤徐放手段は表面積を増加させるための穴又は溝を備えることを特徴とする。 [0009] sustained drug release means (4) (2) is characterized by having a hole or groove for increasing the surface area.

【0010】(5) (1)の薬剤徐放手段は、液体の薬剤または液体に溶解した薬剤を保持するとともに眼内に挿入後に保持した薬剤を徐放するための多数の穴を持つことを特徴とする。 [0010] (5) a drug release means (1) is to have a large number of holes for sustained release of drug retained after insertion into the eye holds the drug dissolved in the drug or liquid fluid and features.

【0011】(6) (5)の薬剤徐放手段は、光学部もしくは支持部に取り付け又は一体的に形成されることを特徴とする。 [0011] (6) a drug release means (5) is characterized in that it is attached or integrally formed with the optic portion or support portion.

【0012】 [0012]

【実施例1】以下、本発明の一実施例を図面に基づいて説明する。 Example 1 will be described below with reference to an embodiment of the present invention with reference to the accompanying drawings. 図1は本発明に係る眼内レンズの平面形状を示した図である。 Figure 1 is a diagram showing a planar shape of the intraocular lens according to the present invention. 1は屈折力を持った光学部であり、一般には凸レンズに形成される。 1 is an optical unit having a refractive power, typically are formed in a convex lens. 2は光学部1を眼内に支持固定するための支持部であり、支持部2は光学部1の径方向に対向して周方向に湾曲して2本延び、支持部2 2 is a support part for supporting and fixing the optical unit 1 into the eye, the supporting portion 2 extends two curved in circumferential direction to face in the radial direction of the optical unit 1, support 2
の弾性力により光学部1は眼内の所定位置に支持される。 The optical unit 1 by the elastic force of being supported at a predetermined position within the eye. 光学部1と支持部2は一体的に形成され、いわゆるワンピ−スタイプと称される眼内レンズである。 The optical unit 1 and the support 2 are integrally formed, so-called dress - a Stipe called intraocular lens. その材質はPMMAを主成分として、紫外線吸収剤等の色素を分散させている。 The material is mainly of PMMA, it is dispersed dye such as an ultraviolet absorber.

【0013】3は炎症や後発白内障などの術後合併症を抑制する治療薬を含有させる薬剤含有部である。 [0013] 3 is a drug-containing unit to contain inhibiting therapeutic agent postoperative complications such as inflammation and cataract. 薬剤含有部3は手術操作の障害とならないように、支持部2の光学部側に取り付けられている。 Drug-containing unit 3 are so as not interfere with the surgical operation, attached to the optical portion of the support 2. 薬剤含有部3は含水性又は含油性ポリマ−の材質(もちろん含水性でかつ含油性の材質であっても差支えない)からなり、液体の薬剤あるいは液体に溶解された薬剤を含有することができるとともに、その薬剤を眼内で徐々に放出する機能(徐放機能)を有している。 Drug-containing unit 3 a water or oil-containing polymer - consists of a material (of course permissible not be the material of the water-containing and and oil retainability) can contain a drug dissolved in the drug or liquid in the liquid together, and has a function (slow release function) for gradual release of the drug in the eye. この機能を有する材質としては、 The material having this feature,
ポリビニルピロリドン、ポリヒドロキシエチルメタクリレ−ト、ヂメチルホルムアミド、ポリビニルアルコ− Polyvinylpyrrolidone, hydroxyethyl methacrylate - DOO, diethylene methyl formamide, polyvinyl alcohol -
ル、ポリリン酸等に代表される材質が挙げられる。 Le include a material represented by polyphosphoric acid.

【0014】薬剤含有部3の支持部2への取り付けは、 [0014] Attachment to the support portion 2 of the drug-containing unit 3,
接着等周知の方法により物理的に取り付けることができる他、化学結合によっても行うことができる(両者の併用であっても構わない)。 Other capable physically attached by bonding or the like known method can be carried out by a chemical bond (may be a combination of the both). なお、薬剤含有部は必要に応じてその体積を変えることができる。 Incidentally, the drug-containing unit can change its volume if necessary. 薬剤含有部3への薬剤の含有は、眼内レンズ挿入手術の直前に行うこともできるが、眼内レンズの製造時に予め含ませておくこともできる。 Inclusion of the drug into the drug-containing unit 3 can also be carried out just before the intraocular lens surgery, can also be made to contain in advance at the time of manufacture of the intraocular lens. 特に、溶液に溶解するタイプの薬剤においては、予め含ませた後に溶媒のみを乾燥除去することで、 In particular, in the type of drug dissolved in a solution, by only removed by drying the solvent after moistened in advance,
薬剤含有部3の分子マトリックスの中に長期にわたり薬剤を保管させておくことができる。 It can be allowed to store the drug over time into the molecular matrix of the drug-containing unit 3.

【0015】このような構成の眼内レンズは、薬剤含有部3が薬剤のタンクあるいは担体といった役割を果たして眼内に薬剤を持ち込む。 The intraocular lens of such a configuration, bringing the drug into the eye drug-containing unit 3 plays a role, such as tanks or carrier agents. そして、眼内に挿入された薬剤含有部3は、眼内で適当な期間にわたり薬剤を徐放するようになる。 The drug-containing unit 3 inserted into the eye, so that sustained release of the drug over a suitable period of time in the eye.

【0016】この薬剤含有部3による薬剤の徐放効果を、本出願人は次のような実験を行い確認した。 [0016] The sustained-release effect of the drug by the drug-containing unit 3, the applicant was confirmed perform the following experiment. まず、 First of all,
図2に示す如く中心部10がPMMA、周辺部11がP Heart 10 as shown in FIG. 2 is PMMA, the peripheral portion 11 is P
HEMAからなるボタン状のものを作成する。 To create what button-shaped consisting of HEMA. 作成方法は、周知の技術によりPMMAのロッドを作成した後、 Creation method, after creating a rod of PMMA by known techniques,
PMMAロッド周囲をPHEMAモノマ−で満たしたす。 It is filled with - the PMMA rod around PHEMA monomer. その後、重合開始剤を加え加熱し重合硬化させ、これを機械加工により厚さ2mm程の寸法で切り出す。 Thereafter, the polymerization initiator is added heat polymerizing and curing, which cut in dimensions of thickness of about 2mm by machining. このボタン状のものに染料を薬剤に見立て含有させた後、 After the dye was contained likened to drugs to those of the button-shaped,
所定量の水溶液中に浸し、その濃度を時間をおって測定した。 Immersed in a predetermined amount of an aqueous solution thereof was measured concentration over time. その結果、徐放効果は図3のグラフに示すように1週間以上にわたることが確認できた。 As a result, sustained release effect was confirmed that for over a week as shown in the graph of FIG.

【0017】なお、上記の実施例では、薬剤含有部3を支持部2へ取り付けた例を示したが、薬剤含有部3の取り付けは、手術操作の障害や光学的性能に影響を与えない位置が好ましく、例えば図4に示す位置等種々の部分に取り付けることができる(図中の斜線で示す部分が薬剤含有部である)。 [0017] In the above embodiment, although the example in which the drug-containing unit 3 to the support 2, the attachment of the drug-containing unit 3 does not affect the failure and optical performance of the surgical operating position it is preferred, for example, can be mounted in a position such as various parts shown in FIG. 4 (a portion indicated by oblique lines in the figure is a drug-containing unit). 図4の(a)は光学部1の周回りに取り付けた例、(b)は支持部2自体を薬剤含有部とした例、(c)は光学部1の裏面(または表面)に取り付けた例である。 Examples of (a) is attached to the peripheral around the optical unit 1 FIG 4, (b) the example of the supporting portion 2 itself to the drug-containing unit, attached to (c) the back surface of the optical unit 1 (or surface) it is an example. (d)は光学部1と支持部2とを別個に加工した後、これをカシメ等により接合したいわゆるスリ−ピ−スタイプの眼内レンズへの取り付け例であり、 (D) shows after separately processed optical part 1 and the support 2, so-called ground which was joined by caulking - peak - a mounting example of the intraocular lens Stipe,
薬剤含有部は円板状の部分からのびた足がカシメ等により光学部1に取り付けられている。 Drug-containing unit is a foot extending from the disc-shaped part is attached to the optical unit 1 by caulking or the like. (e)のものは薬剤含有部に穴を設けた例であり、この場合、薬剤含有部の表面積を増加させることができるので、薬剤の吸収、徐放の速度を制御することも可能となる。 Those of (e) is an example in which a hole in the drug-containing unit, in this case, it is possible to increase the surface area of ​​the drug-containing unit, it is possible to control drug absorption, the rate of sustained release . また穴を設ける代わりに溝を設けるようにしてもよい。 Or it may be provided with grooves instead of providing the hole.

【0018】なお、薬剤含有部3に含有させる薬剤は、 [0018] Incidentally, the drug to be contained in the drug-containing unit 3,
一つに限られるわけではなく、複数であっても良い。 Not limited to the one, it may be a plurality. 複数の薬剤を含有させる場合は、薬剤含有部3を複数設けることにより別々に含有させることもできる。 The case of containing a plurality of drug may be contained separately by providing a plurality of drug-containing unit 3.

【0019】 [0019]

【実施例2】図5は実施例2の眼内レンズの平面形状を示した図である。 Second Embodiment FIG. 5 is a view showing the planar shape of the intraocular lens in Example 2. 3´は多数の穴3´aを持った薬剤保持部であり、薬剤保持部3´は支持部2´及び光学部1 3'are drug holding part having a plurality of holes 3'a, drug holding part 3 'support portion 2' and the optical unit 1
´とともに一体的に形成されたものである。 Those which are integrally formed with '. 材質はPM The material is PM
MA等周知のものが使用でき、表面処理が施されたものであってもよい。 Those known can be used, such as MA, or may be surface-treated.

【0020】実施例2の眼内レンズにおいては、薬剤保持部3´に開けられた多数の穴3´aに薬剤あるいは薬剤溶液を染み込ませることにより、この多数の穴が薬剤を眼内に持ち込む担体の役目を果たす。 [0020] In the intraocular lens of Example 2, by the number of holes 3'a drilled in the drug holding portion 3'impregnated drug or drug solution, bring this number of holes drug into the eye It serves as a carrier. 薬剤を薬剤保持部3´の穴3´aに含有させるのは、実施例1と同様に眼内レンズ挿入手術直前に行ってもよいし、製造時に予め含ませておくこともできる。 Drug for inclusion in the hole 3'a of the drug holding part 3 'may be performed in the same manner as intraocular lens insertion operation immediately before that of Example 1, it can also be made to contain in advance at the time of manufacture. 溶液に溶解するタイプの薬剤の場合は、予め含ませた後溶媒のみ乾燥除去することで、結晶、あるいは紛体の状態で穴に保持され、長期にわたり容易に薬剤を保管できる。 For the type of drug dissolved in a solution, by only drying and removing the solvent after previously contained, crystalline, or is held in a hole in the state of powder, it can be easily stored drug over time. さらにこの状態にすると、溶解した後に薬剤としての機能を果たすまでの時間が溶液の状態のときより長くかかるため、長期間の徐放効果が期待できる(徐放効果が早く必要な場合は、挿入前に溶液に戻して行っても良い)。 Further With this state, the time to serve as a drug after dissolution takes longer than in the state of a solution, if the long-term sustained release effect is required fast (slow release effect can be expected for the insertion may be carried back to the solution before).

【0021】薬剤保持部3´による薬剤の保持能力を、 [0021] the retention capacity of the drug by drug holding part 3 ',
本出願人は次のような実験を行い確認した。 The applicant was confirmed perform the following experiment. 図6に示すごとく、PMMAのロッドを周知の技術により旋盤加工し、中心部20を光学部としてその周辺部21にドリルにより0.3mmの穴22を多数開ける。 As shown in FIG. 6, the rod of PMMA lathed by known techniques, opens a number of holes 22 of 0.3mm with a drill at its periphery 21 to the center section 20 as an optical unit. その後、研磨を施す。 Then, it is polished. これに濃度30%の塩化ナトリウム水溶液を薬剤に見立て穴22に染み込ませた後、溶媒である水を蒸発乾燥させて穴の中に塩化ナトリウムの結晶を保持させた。 After this 30% strength aqueous sodium chloride solution impregnated into the hole 22 likened to drugs, and the water is the solvent evaporated to dryness to hold the sodium chloride crystals in the hole. この結果、アサンプル穴内に0.68gの塩化ナトリウムを保持していた。 As a result, it retained sodium chloride 0.68g in A sample hole.

【0022】実施例2の眼内レンズにおいても、実施例1と同様に薬剤保持部3´を設ける位置は種々の位置に設けることが可能である(図7参照)。 [0022] Also in the intraocular lens of Example 2, the position where the likewise drug holding part 3 'of Example 1 can be provided in various positions (see Fig. 7). また、薬剤保持部3´の体積及び穴3´aの大きさも必要に応じて変えることができる。 Further, it is possible to vary depending also required size of the volume of the drug holding part 3 'and the hole 3'a.

【0023】 [0023]

【発明の効果】以上説明したように、本発明の眼内レンズによれば、眼内レンズ手術における術後合併症の抑制や術前からの内眼的疾患の治療のために必要な薬剤を眼内レンズに十分に付与できるため、薬剤の投与を効率良く行うことができる。 As described in the foregoing, according to the intraocular lens of the present invention, the drug required for the treatment of intraocular disorders from previous suppression and operative postoperative complications in intraocular lens surgery since sufficiently imparted to the intraocular lens, it can be efficiently administered drugs. これにより、さらに高い手術の安全性と質の高い視機能供与への寄与が可能となる。 This allows the contribution to higher safety and high quality visual function donor surgery.

【図面の簡単な説明】 BRIEF DESCRIPTION OF THE DRAWINGS

【図1】実施例1の眼内レンズの平面形状を示す図である。 1 is a diagram showing a planar shape of the intraocular lens in Example 1.

【図2】薬剤の徐放効果を確認するために行った実験のテストサンプルを示す図である。 2 is a diagram showing a test sample of an experiment performed for confirming the sustained release effect of the drug.

【図3】図2のテストサンプルの徐放効果を示す図である。 3 is a diagram showing a sustained release effect of the test sample of FIG.

【図4】実施例1における薬剤含有部3の他の取り付け位置の例を示した図である。 4 is a diagram showing an example of another attachment position of the drug-containing unit 3 in the first embodiment.

【図5】実施例2の眼内レンズの平面形状を示した図である。 5 is a diagram showing a planar shape of the intraocular lens in Example 2.

【図6】薬剤保持部3´による薬剤の保持能力を確認するために行った実験のテストサンプルを示す図である。 6 is a diagram showing a test sample of an experiment performed for confirming the retention of the drug by the drug holding part 3 '.

【図7】薬剤保持部3´を設ける位置の他の例を示した図である。 7 is a diagram showing another example of a position where the drug holding part 3 '.

【符号の説明】 DESCRIPTION OF SYMBOLS

1 光学部 2 支持部 3 薬剤含有部 3´ 薬剤保持部 3´a 穴 First optical unit 2 support 3 drug-containing 3'drug holding part 3'a hole

───────────────────────────────────────────────────── ────────────────────────────────────────────────── ───

【手続補正書】 [Procedure amendment]

【提出日】平成7年6月30日 [Filing date], 1995 June 30,

【手続補正1】 [Amendment 1]

【補正対象書類名】明細書 [Correction target document name] specification

【補正対象項目名】請求項1 [Correction target item name] according to claim 1,

【補正方法】変更 [Correction method] change

【補正内容】 [Correction contents]

【手続補正2】 [Amendment 2]

【補正対象書類名】明細書 [Correction target document name] specification

【補正対象項目名】0006 [Correction target item name] 0006

【補正方法】変更 [Correction method] change

【補正内容】 [Correction contents]

【0006】 [0006]

【課題を解決するための手段】本発明は、上記課題を解決するために、次のような構成を持つことを特徴とする。 SUMMARY OF THE INVENTION The present invention, in order to solve the above problems, characterized by having the following configuration. (1) 水晶体を取り除いた後に眼内に挿入される眼内レンズにおいて、薬剤を吸収もしくは保持するとともに、眼内に挿入後に吸収もしくは保持した薬剤を徐々に眼内に放出する薬剤除放手段を設けたことを特徴とする。 (1) In the intraocular lens to be inserted into the eye after removal of the crystalline lens, while absorbing or retaining a drug, a drug sustained-release means for releasing a drug absorbed or retained after insertion into the eye gradually into the eye characterized by providing.

Claims (6)

    【特許請求の範囲】 [The claims]
  1. 【請求項1】 水晶体を取り除いた後に眼内に挿入される眼内レンズにおいて、液体の薬剤または液体に溶解した薬剤を吸収もしくは保持するとともに、眼内に挿入後に吸収もしくは保持した薬剤を徐々に眼内に放出する薬剤徐放手段を設けたことを特徴とする眼内レンズ。 1. A intraocular lens to be inserted into the eye after removal of the crystalline lens, while absorbing or retaining the agent dissolved in the drug or liquid fluid, slowly drug absorbed or retained after insertion into the eye intraocular lens, characterized in that a drug release means for releasing into the eye.
  2. 【請求項2】 請求項1の薬剤徐放手段の材質は含水性又は含油性の材質からなり、液体の薬剤または液体に溶解した薬剤を吸収含有することを特徴とする眼内レンズ。 Wherein wherein the material of the drug release means of claim 1 comprises water or oil retainability material, intraocular lens, characterized by containing absorbing agent dissolved in the drug or liquid fluid.
  3. 【請求項3】 請求項2の眼内レンズは、屈折力を持つ光学部と、該光学部を眼内に支持固定するための支持部を有し、前記薬剤徐放手段は前記光学部または支持部に取り付けたことを特徴とする眼内レンズ。 3. Intraocular lens according to claim 2, the optical portion having a refractive power, the light faculty has a support portion for supporting and fixing into the eye, the drug release means is the optical unit or intraocular lens, characterized in that attached to the support portion.
  4. 【請求項4】 請求項2の薬剤徐放手段は表面積を増加させるための穴又は溝を備えることを特徴とする眼内レンズ。 4. A drug release means according to claim 2 intraocular lens characterized by comprising a hole or groove for increasing the surface area.
  5. 【請求項5】 請求項1の薬剤徐放手段は、液体の薬剤または液体に溶解した薬剤を保持するとともに眼内に挿入後に保持した薬剤を徐放するための多数の穴を持つことを特徴とする眼内レンズ。 Drug controlled release means 5. The method of claim 1, characterized by having a number of holes for sustained release of drug retained after insertion into the eye holds the drug dissolved in the drug or liquid fluid intraocular lens to be.
  6. 【請求項6】 請求項5の薬剤徐放手段は、光学部もしくは支持部に取り付け又は一体的に形成されることを特徴とする眼内レンズ。 6. Pharmaceutical controlled release means according to claim 5, intraocular lens, characterized in that it is attached or integrally formed with the optic portion or support portion.
JP26468694A 1994-10-03 1994-10-03 Intraocular lens Expired - Fee Related JP3640690B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP26468694A JP3640690B2 (en) 1994-10-03 1994-10-03 Intraocular lens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26468694A JP3640690B2 (en) 1994-10-03 1994-10-03 Intraocular lens

Publications (2)

Publication Number Publication Date
JPH08103457A true JPH08103457A (en) 1996-04-23
JP3640690B2 JP3640690B2 (en) 2005-04-20

Family

ID=17406794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP26468694A Expired - Fee Related JP3640690B2 (en) 1994-10-03 1994-10-03 Intraocular lens

Country Status (1)

Country Link
JP (1) JP3640690B2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030566A1 (en) * 1998-11-20 2000-06-02 Staar Surgical Company, Inc. Posterior chamber intraocular implant device, and packaging therefor
JP2005523049A (en) * 2002-01-31 2005-08-04 シメッド ライフ システムズ インコーポレイテッドScimed Life Systems,Inc. Medical devices for the release of biologically active substances
US20060271177A1 (en) * 2003-05-28 2006-11-30 Christie Bruce A Mask configured to maintain nutrient transport without producing visible diffraction patterns
WO2007112946A1 (en) * 2006-03-30 2007-10-11 Universite De Geneve Intraocular lens with drug delivery system attached thereto
US20110040378A1 (en) * 2007-01-29 2011-02-17 Werblin Research & Development Corp. Intraocular lens system
JP2014090772A (en) * 2012-11-01 2014-05-19 Chukyo Medical Co Inc Intraocular implant, intraocular implant set, and intraocular lens
US9005281B2 (en) 2009-08-13 2015-04-14 Acufocus, Inc. Masked intraocular implants and lenses
US9204962B2 (en) 2013-03-13 2015-12-08 Acufocus, Inc. In situ adjustable optical mask
US9326845B2 (en) 2014-04-24 2016-05-03 Chukyo Medical Co., Inc. Intraocular implant, intraocular implant set and intraocular lens
US9427311B2 (en) 2009-08-13 2016-08-30 Acufocus, Inc. Corneal inlay with nutrient transport structures
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
US9545303B2 (en) 2011-12-02 2017-01-17 Acufocus, Inc. Ocular mask having selective spectral transmission
US9943403B2 (en) 2014-11-19 2018-04-17 Acufocus, Inc. Fracturable mask for treating presbyopia
US10004593B2 (en) 2009-08-13 2018-06-26 Acufocus, Inc. Intraocular lens with elastic mask

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030566A1 (en) * 1998-11-20 2000-06-02 Staar Surgical Company, Inc. Posterior chamber intraocular implant device, and packaging therefor
JP2005523049A (en) * 2002-01-31 2005-08-04 シメッド ライフ システムズ インコーポレイテッドScimed Life Systems,Inc. Medical devices for the release of biologically active substances
US9138142B2 (en) * 2003-05-28 2015-09-22 Acufocus, Inc. Masked intraocular devices
US20060271177A1 (en) * 2003-05-28 2006-11-30 Christie Bruce A Mask configured to maintain nutrient transport without producing visible diffraction patterns
US8858624B2 (en) 2003-05-28 2014-10-14 Acufocus, Inc. Method for increasing the depth of focus of a patient
WO2007112946A1 (en) * 2006-03-30 2007-10-11 Universite De Geneve Intraocular lens with drug delivery system attached thereto
US20110040378A1 (en) * 2007-01-29 2011-02-17 Werblin Research & Development Corp. Intraocular lens system
US9398949B2 (en) * 2007-01-29 2016-07-26 Emmetropia, Inc. Intraocular lens system
US9492272B2 (en) 2009-08-13 2016-11-15 Acufocus, Inc. Masked intraocular implants and lenses
US10004593B2 (en) 2009-08-13 2018-06-26 Acufocus, Inc. Intraocular lens with elastic mask
US9005281B2 (en) 2009-08-13 2015-04-14 Acufocus, Inc. Masked intraocular implants and lenses
US9427311B2 (en) 2009-08-13 2016-08-30 Acufocus, Inc. Corneal inlay with nutrient transport structures
US9848979B2 (en) 2011-12-02 2017-12-26 Acufocus, Inc. Ocular mask having selective spectral transmission
US9545303B2 (en) 2011-12-02 2017-01-17 Acufocus, Inc. Ocular mask having selective spectral transmission
JP2014090772A (en) * 2012-11-01 2014-05-19 Chukyo Medical Co Inc Intraocular implant, intraocular implant set, and intraocular lens
US9603704B2 (en) 2013-03-13 2017-03-28 Acufocus, Inc. In situ adjustable optical mask
US9204962B2 (en) 2013-03-13 2015-12-08 Acufocus, Inc. In situ adjustable optical mask
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
US9573328B2 (en) 2013-03-14 2017-02-21 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
US9844919B2 (en) 2013-03-14 2017-12-19 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
US10183453B2 (en) 2013-03-14 2019-01-22 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
US9326845B2 (en) 2014-04-24 2016-05-03 Chukyo Medical Co., Inc. Intraocular implant, intraocular implant set and intraocular lens
US9943403B2 (en) 2014-11-19 2018-04-17 Acufocus, Inc. Fracturable mask for treating presbyopia

Also Published As

Publication number Publication date
JP3640690B2 (en) 2005-04-20

Similar Documents

Publication Publication Date Title
Apple et al. A comparison of ciliary sulcus and capsular bag fixation of posterior chamber intraocular lenses
EP0269288B1 (en) Intraocular lenses
US5326506A (en) Method for making a composite intraocular lens
US4449257A (en) Intraocular lens and method of retaining in place
US5035710A (en) Balloon for an intraocular lens and processes for its production
AU761684B2 (en) Minicapsulorhexis valve
JP3725431B2 (en) Water plasticized high refractive index polymers for ophthalmic
JP3859712B2 (en) Increasing the lumen artificial heart valves
EP2464311B1 (en) Masked intraocular implants and lenses
US4888016A (en) "Spare parts" for use in ophthalmic surgical procedures
ES2319802T3 (en) System IOLs.
JP3375841B2 (en) Use of the polymerizable yellow dye and an ophthalmic lens
KR100819895B1 (en) Expandable medical device for delivery of beneficial agent
EP1531875B1 (en) Active agent delivery system including a poly(ethylene-co-(meth)acrylate), medical device, and method
JP3958576B2 (en) Accommodating intraocular lens
JP2823692B2 (en) A flat-screen intraocular lens
EP2034937B1 (en) Intraocular implants and methods and kits therefor
KR101494921B1 (en) Accommodative intraocular lens having a haptic plate
US20050277864A1 (en) Injectable gel implant for glaucoma treatment
CA2295946C (en) Method of preparing foldable hydrophilic ophthalmic device materials
JP5748389B2 (en) They include absorbable matrix material and antiproliferative agents, implantable devices and methods for preventing or treating dysfunction of hemodialysis vascular access and other vascular grafts
US20050015144A1 (en) Intraocular lens system
EP1806107A1 (en) Devices for treating vulnerable plaque
US5628795A (en) Spare parts for use in ophthalmic surgical procedures
US20040117006A1 (en) Drug delivery from stents

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Effective date: 20040413

Free format text: JAPANESE INTERMEDIATE CODE: A131

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040728

A521 Written amendment

Effective date: 20040921

Free format text: JAPANESE INTERMEDIATE CODE: A523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050105

A61 First payment of annual fees (during grant procedure)

Effective date: 20050119

Free format text: JAPANESE INTERMEDIATE CODE: A61

R150 Certificate of patent (=grant) or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 3

Free format text: PAYMENT UNTIL: 20080128

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 4

Free format text: PAYMENT UNTIL: 20090128

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090128

Year of fee payment: 4

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 5

Free format text: PAYMENT UNTIL: 20100128

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 6

Free format text: PAYMENT UNTIL: 20110128

LAPS Cancellation because of no payment of annual fees